BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 35149964)

  • 1. Treatment Outcome of Wet Age-Related Macular Degeneration Management in Thailand: A Retrospective Real-World Study (TOWER Study).
    Thoongsuwan S; Hanutsaha P; Chantarasorn Y; Ruamviboonsuk P; Vongkulsiri S; Kungwanpongpun P
    Ophthalmol Ther; 2022 Apr; 11(2):739-757. PubMed ID: 35149964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-World Effectiveness and Real-World Cost-Effectiveness of Intravitreal Aflibercept and Intravitreal Ranibizumab in Neovascular Age-Related Macular Degeneration: Systematic Review and Meta-Analysis of Real-World Studies.
    Carrasco J; Pietsch GA; Nicolas MP; Koerber C; Bennison C; Yoon J
    Adv Ther; 2020 Jan; 37(1):300-315. PubMed ID: 31728825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management and Outcomes for Neovascular Age-Related Macular Degeneration: Analysis of United States Electronic Health Records.
    Kiss S; Campbell J; Almony A; Shih V; Serbin M; LaPrise A; Wykoff CC
    Ophthalmology; 2020 Sep; 127(9):1179-1188. PubMed ID: 32345477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration: The LATAR Study: Report 1: Ten-Year, Real-World Outcomes.
    Spooner K; Fraser-Bell S; Hong T; Phan L; Wong JG; Chang A
    Ophthalmol Retina; 2021 Jun; 5(6):511-518. PubMed ID: 33007523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Visual Acuity Outcomes and Anti-Vascular Endothelial Growth Factor Therapy Intensity in Neovascular Age-Related Macular Degeneration Patients: A Real-World Analysis of 49 485 Eyes.
    Ciulla TA; Hussain RM; Pollack JS; Williams DF
    Ophthalmol Retina; 2020 Jan; 4(1):19-30. PubMed ID: 31324588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Twelve-month outcomes of intra-vitreal anti-VEGF agents for treatment-naïve neovascular age-related macular degeneration eyes: French data from the fight for retinal blindness!
    Lestable L; Gabrielle PH; Bron AM; Nguyen P; Creuzot-Garcher C
    J Fr Ophtalmol; 2020 Oct; 43(8):761-769. PubMed ID: 32622633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of injection frequency on 5-year real-world visual acuity outcomes of aflibercept therapy for neovascular age-related macular degeneration.
    Chandra S; Rasheed R; Menon D; Patrao N; Lamin A; Gurudas S; Balaskas K; Patel PJ; Ali N; Sivaprasad S
    Eye (Lond); 2021 Feb; 35(2):409-417. PubMed ID: 32265509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treat-and-extend therapy using intravitreal aflibercept for neovascular age-related macular degeneration: 2-year real-world practice data from Slovenia.
    Jaki Mekjavić P; Gregorčič B; Oberč C; Podgoršek S
    BMC Ophthalmol; 2018 Dec; 18(1):333. PubMed ID: 30572850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two-year results of a combined regimen of aflibercept treatment in three types of choroidal neovascular membrane in the wet form of age-related macular degeneration: Real-life evidence in the Czech Republic.
    Stepanov A; Nemcansky J; Veith M; Manethova K; Stredova M; Pencak M; Tarkova A; Studnicka J
    Eur J Ophthalmol; 2021 Sep; 31(5):2488-2495. PubMed ID: 33198503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ten-year outcomes of antivascular endothelial growth factor therapy in neovascular age-related macular degeneration.
    Chandra S; Arpa C; Menon D; Khalid H; Hamilton R; Nicholson L; Pal B; Fasolo S; Hykin P; Keane PA; Sivaprasad S
    Eye (Lond); 2020 Oct; 34(10):1888-1896. PubMed ID: 31980748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-World Visual And Clinical Outcomes For Patients With Neovascular Age-Related Macular Degeneration Treated With Intravitreal Ranibizumab: An 8-Year Observational Cohort (AMD8).
    Horner F; Lip PL; Clark H; Chavan R; Sarmad A; Mushtaq B
    Clin Ophthalmol; 2019; 13():2461-2467. PubMed ID: 31849444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Importance of continuous treatment with intravitreal aflibercept injections in patients with neovascular age-related macular degeneration-12-month post hoc analysis of the PERSEUS real-world evidence study.
    Wachtlin J; Eter N; Hasanbasic Z; Keramas G; Rech C; Sachs H; Schilling H; Wiedemann P; Framme C
    Graefes Arch Clin Exp Ophthalmol; 2021 Mar; 259(3):601-611. PubMed ID: 32789651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of Continued Ranibizumab Therapy in Neovascular Age-Related Macular Degeneration versus Switch to Aflibercept: Real World Evidence.
    Chakravarthy U; Bezlyak V; Sagkriotis A; Griner R; Skelly A; Boyer DS; Milnes F
    Ophthalmol Retina; 2019 Jan; 3(1):8-15.e1. PubMed ID: 30929819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Twelve-Month Outcomes of Ranibizumab vs. Aflibercept for Neovascular Age-Related Macular Degeneration: Data from an Observational Study.
    Gillies MC; Nguyen V; Daien V; Arnold JJ; Morlet N; Barthelmes D
    Ophthalmology; 2016 Dec; 123(12):2545-2553. PubMed ID: 27707549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration.
    Solomon SD; Lindsley K; Vedula SS; Krzystolik MG; Hawkins BS
    Cochrane Database Syst Rev; 2019 Mar; 3(3):CD005139. PubMed ID: 30834517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion.
    Shalchi Z; Mahroo O; Bunce C; Mitry D
    Cochrane Database Syst Rev; 2020 Jul; 7(7):CD009510. PubMed ID: 32633861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Longer-Term Anti-VEGF Therapy Outcomes in Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema, and Vein Occlusion-Related Macular Edema: Clinical Outcomes in 130 247 Eyes.
    Ciulla TA; Hussain RM; Taraborelli D; Pollack JS; Williams DF
    Ophthalmol Retina; 2022 Sep; 6(9):796-806. PubMed ID: 35381391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-vascular endothelial growth factor therapy in diabetic macular edema: real-life outcomes from a multicenter study in Turkey over 36 months.
    Durukan AH; Unlu N; Onen M; Alp MN; Yeşiltaş YS; Kalayci D; Acar MA; Sekeroglu MA; Citirik M; Altintas AGK; Hazirolan D; Kucukevcilioglu M; Ozdal PC; Toklu Y; Bicer T; Ugurlu N; Budakoglu O; Yazar Z; Ucgun NI; Serdar K; Doguizi S; Erol YO; Atilgan CU; Yorgun MA; Soba DO; Berker N; Baskan C; Yilmaz ES
    Int Ophthalmol; 2022 Dec; 42(12):3777-3787. PubMed ID: 35829865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravitreal Ranibizumab for neovascular Age-related macular degeneration in clinical practice: five-year treatment outcomes.
    Zhu M; Chew JK; Broadhead GK; Luo K; Joachim N; Hong T; Syed A; Chang AA
    Graefes Arch Clin Exp Ophthalmol; 2015 Aug; 253(8):1217-25. PubMed ID: 25205618
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Consistent Long-Term Therapy of Neovascular Age-Related Macular Degeneration Managed by 50 or More Anti-VEGF Injections Using a Treat-Extend-Stop Protocol.
    Adrean SD; Chaili S; Ramkumar H; Pirouz A; Grant S
    Ophthalmology; 2018 Jul; 125(7):1047-1053. PubMed ID: 29439828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.